{"filings":[{"id":2078813,"accession_number":"0001683168-26-005988","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2026-08-05T20:05:47+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign reports record Q2 revenue $28.3M (+48%), raises FY2026 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $28.25M, up 48.1% YoY; GAAP net income $6.76M ($0.11 EPS) vs $1.39M ($0.02) prior year.","Pharma revenue $14.65M (+88.9%) with 148 active programs; plasma revenue $13.04M (+21.4%) with 561 centers.","Adjusted EBITDA $9.61M, up 113%; operating margin 24.8% (21.3% ex contingent consideration).","Raised FY2026 revenue guidance to $114-117M and adjusted EBITDA to $35-38M.","Balance sheet: $27.37M unrestricted cash, zero bank debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49444,"accession_number":"0001683168-26-003748","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2026-05-12T23:29:04+00:00","items":["5.07"],"status":"ready","headline":"Paysign shareholders elect all seven directors, ratify Baker Tilly as auditor at May 8 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each director nominee received >34.8M votes for; Newcomer 37.3M, Triplett 34.9M, others in between.","Baker Tilly ratified as independent auditor for FY 2026 with 38.4M for, 279 against, 96K abstain.","Broker non-votes were 641,671 on both proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40244,"accession_number":"0001683168-26-003722","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2026-05-12T20:05:48+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q1 2026 revenue $28.04M (+50.8% YoY); pharma up 81.9%, net income $5.44M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $28.04M, up 50.8% YoY; pharma $15.68M (+81.9%), plasma $11.75M (+24.9%).","Net income $5.44M ($0.09 diluted EPS) vs $2.59M ($0.05); adj. EBITDA $10.59M, up 113.4%.","Operating margin 23.8% vs 13.4% YoY; gross margin 65.0% from 62.9% on pharma mix shift.","Active patient affordability programs 135 (net +45 in 12 months); plasma centers 573 (net +89).","Q2 2026 guidance: revenue $26.2M-$26.7M; full-year revenue $106.5M-$110.5M, net income $13M-$16M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104605,"accession_number":"0001683168-26-002168","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign FY2025 revenue $82.0M (+40.5%); guides FY2026 revenue $106.5-110.5M, net income nearly doubles","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 total revenues $82.0M (up 40.5% YoY); net income $7.55M ($0.13 diluted EPS) vs $3.82M ($0.07) in 2024.","Adjusted EBITDA $19.94M (up 107.3% YoY); pharma revenue +167.8% to $33.89M on 55 new patient affordability programs.","Added 115 net plasma centers (595 total); plasma revenue +4.0% to $45.62M.","Gamma acquisition (BECS under FDA review) closed March 2025; exited with $21.07M cash, zero debt.","FY2026 guidance: revenue $106.5-110.5M (30-35% growth), net income $13-16M ($0.21-0.26 EPS), adjusted EBITDA $30-33M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120881,"accession_number":"0001683168-25-008270","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q3 revenue $21.6M (+41.6% YoY); raises full-year 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $21.6M (+41.6% YoY); net income $2.22M (+54.2% YoY); diluted EPS $0.04 vs $0.03 YoY.","Adjusted EBITDA $5.04M (23.3% margin), up 78.1% YoY; pharma patient affordability revenue surged 141.9% to $7.92M.","Plasma revenue grew 12.4% to $12.86M; exited with 595 plasma centers (down 12 QoQ) and 105 active pharma programs (up 8 QoQ).","Raises FY2025 guidance: revenue $80.5M–$81.5M (38.7% YoY midpoint), net income $7.0M–$8.0M, Adjusted EBITDA $19.0M–$20.0M.","Ended quarter with $7.53M unrestricted cash, zero bank debt; opened new 30,000 sq ft customer service center."],"consensus_eps_estimate":0.0204,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":59272980.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137480,"accession_number":"0001683168-25-007009","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Paysign proposes settlement of four derivative actions; court hearing set for Nov 14, 2025","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves four stockholder derivative actions alleging violations of Exchange Act and fiduciary duties.","Company will implement corporate governance reforms; no admission of fault or wrongdoing.","Final approval hearing scheduled for November 14, 2025 before Judge Boulware in Nevada federal court.","Defendants' insurers to pay $607,500 for attorneys' fees and expenses, subject to court approval.","Settlement requires dismissal of all actions with prejudice; releases all claims against named individuals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137479,"accession_number":"0001683168-25-005668","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q2 revenue $19.08M (+33%), net income $1.39M (+99%), raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $19.08M (+33.1% YoY), net income $1.39M (+99.1%), diluted EPS $0.02; Adj. EBITDA $4.51M (+101.8%), $0.08 per share.","Pharma patient affordability revenue surged 189.9% to 40.6% of total; added 7 net programs, now 97 active.","Added 123 net plasma centers in Q2, exiting with 607; plasma revenue down 4.7% due to industry oversupply.","FY2025 guidance raised: revenue $76.5-78.5M, net income $6-7M ($0.10-0.12 diluted EPS), Adj. EBITDA $18-20M.","Q3 2025 guidance: revenue $19.5-20.5M, gross margin ~59%, Adj. EBITDA $4.5-5.0M."],"consensus_eps_estimate":0.0357,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":37676502.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154821,"accession_number":"0001683168-25-004264","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Paysign auditor Moss Adams merges into Baker Tilly; successor appointed","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Moss Adams merged into Baker Tilly US, LLP effective June 3, 2025; Moss Adams resigned as auditor.","Audit Committee approved Baker Tilly as successor independent registered public accounting firm.","No past disagreements or reportable events with Moss Adams for fiscal years 2024 and 2023.","No consultations with Baker Tilly on accounting principles prior to appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154820,"accession_number":"0001683168-25-003453","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Paysign stockholders elect seven directors, approve say-on-pay, ratify Moss Adams","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with over 31M votes for each; broker non-votes ~626K.","Say-on-pay approved on non-binding basis: 31.8M for, 447K against, 231K abstain.","Stockholders voted for say-on-frequency every 3 years (21.5M votes); board adopted that frequency.","Moss Adams LLP ratified as auditor for FY 2025: 33.1M for, ~24.8K against.","Annual meeting held May 7, 2025; results filed May 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154819,"accession_number":"0001683168-25-003288","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q1 2025 revenue up 41% to $18.6M, net income $2.59M; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $18.60M (+41% YoY); net income $2.59M ($0.05 diluted EPS) vs $309K ($0.01) in Q1 2024.","Adjusted EBITDA $4.96M (+193.3%); pharma patient affordability revenue surged 260.8% to 46.3% of revenue.","Added 14 net patient affordability programs (total 90); plasma revenue fell 9.2%, center count 484.","FY2025 guidance raised: revenue $72-74M, net income $6-7M ($0.10-$0.12 EPS), Adj. EBITDA $16-17M.","Q2 2025 revenue guided $18.5-19.0M; Gamma acquisition expected to generate $4-5M annual cash cost savings."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":18598149.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173328,"accession_number":"0001683168-25-001858","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","3.02","7.01","9.01"],"status":"ready","headline":"Paysign Reports FY2024 Revenue of $58.38M and Acquires Gamma Innovation Assets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Full-year 2024 total revenues increased 23.5% to $58.38 million, with pharma patient affordability revenue up 214.5%.","Full-year 2024 net income was $3.82 million ($0.07 per diluted share), down from $6.46 million in 2023 due to prior year tax benefit.","Adjusted EBITDA rose 43.3% to $9.62 million, or $0.17 per diluted share, in 2024.","Acquired assets of Gamma Innovation LLC for cash and 2.5M restricted shares vesting over four years, plus up to 500K earn-out shares.","Appointed Michael Ngo, former Gamma managing member, as Chief Innovation Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190345,"accession_number":"0001683168-24-007620","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q3 revenue up 23% to $15.26M; pharma affordability revenue surges 219%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $15.26M (+23% YoY); net income $1.44M ($0.03 diluted EPS) vs $1.10M ($0.02) prior year.","Pharma patient affordability revenue surged 219.1% YoY, now 21.5% of total revenue; 66 active programs at quarter end.","Adjusted EBITDA $2.83M (+20.6% YoY); FY2024 guidance reaffirmed: rev $56.5-58.5M, adj. EBITDA $9-10M.","Plasma revenue up 3.4% YoY from 478 centers; average monthly revenue per center $7,991, down slightly from $8,041.","Unrestricted cash $10.29M, zero debt; Q4 legal expense expected for class action settlement but within guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":42778104.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206839,"accession_number":"0001683168-24-005176","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q2 2024 revenue up 29.8% to $14.33M; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $697K ($0.01 diluted EPS) vs net loss of $104K in Q2 2023.","Adjusted EBITDA $2.24M, up 95.8% YoY; plasma revenue +12.6%, pharma patient affordability revenue +266.8%.","Added 8 net new plasma centers (477 total) and 8 net new patient affordability programs (61 total) in Q2.","FY 2024 revenue guidance raised to $56.5-$58.5M; adjusted EBITDA guided $9.0-$10.0M (15-17% of revenue).","Exited quarter with $31.29M unrestricted cash and zero debt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":27521673.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224113,"accession_number":"0001683168-24-003052","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q1 revenue $13.2M (+30% YoY); net income $309k vs loss; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $13.2M, up 30% YoY; net income $309k ($0.01 diluted EPS) vs net loss $160k in Q1 2023.","Adjusted EBITDA $1.7M, up 135% from $720k; diluted adj. EBITDA per share $0.03 vs $0.01.","Pharma patient affordability revenue surged 305% YoY; added 10 net new programs, ending quarter with 53 active.","Plasma revenue up 11% YoY; 469 plasma centers (net +5); avg revenue per center per month $7,414 (+5%).","Confirms FY 2024 guidance: revenue $54.5M–$56.7M, adjusted EBITDA $8.0M–$9.0M; Q2 revenue expected +27.5% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":13190074.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224112,"accession_number":"0001683168-24-003032","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PaySign annual meeting elects directors and ratifies auditor for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; Mark R. Newcomer received 33.88M votes for, Jeffrey B. Newman 31.26M.","Moss Adams LLP ratified as independent auditor for FY2024: 34.47M for, 318,485 against, 1,607 abstain.","Broker non-votes of 566,723 recorded on both proposals due to discretionary voting.","Annual meeting held May 3, 2024; results filed under Item 5.07."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224111,"accession_number":"0001683168-24-002525","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Court approves $3.75M settlement of Paysign securities class action; claims dismissed","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Nevada granted final approval of settlement on April 17, 2024.","All claims against Paysign and current/former directors and officers dismissed with prejudice.","Settlement payment of $3.75 million funded entirely from directors-and-officers insurance policy.","Litigation was previously disclosed in Paysign's March 27, 2024 Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243466,"accession_number":"0001683168-24-001715","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign FY2023 revenue up 24% to $47.3M; net income $6.5M; guides FY2024 revenue $54.5-56.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 total revenue $47.3M (+24% YoY); net income $6.5M ($0.12 diluted EPS) vs $1.0M ($0.02) in 2022.","Adjusted EBITDA $6.7M (+21% YoY); Q4 2023 revenue $13.7M (+29% YoY), net income $5.6M ($0.10 diluted EPS).","Plasma centers up 20 net to 464; pharma patient affordability programs up 24 net to 43; revenue from pharma patient affordability +172% YoY.","Exited FY2023 with $17.0M unrestricted cash, zero debt; repurchased 394,558 shares for $1.1M.","FY2024 guidance: revenue $54.5-56.7M, net income $2-3M ($0.04-0.06 diluted EPS), adjusted EBITDA $8-9M ($0.15-0.17 diluted EPS)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243465,"accession_number":"0001683168-24-001505","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Paysign amends bylaws to add Chief Legal Officer role and reflect company name change","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Board approved Second Amended and Restated Bylaws on March 14, 2024.","Added Section 5.13 to define Chief Legal Officer's responsibilities, duties, and powers.","Bylaws updated to reflect company name as \"Paysign, Inc.\"","No mention of an officer appointment; role definition only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243464,"accession_number":"0001683168-24-000505","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Paysign appoints Cambi as COO, Lanford as Chief Payments Officer, Newcomer as President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cosimo Cambi appointed COO effective Jan 24, 2024, succeeding Matt Lanford.","Matt Lanford transitions to Chief Payments Officer to lead new Product and Project Management Office.","Mark Newcomer reappointed as President, taking over Lanford's previous role.","Cambi joined Paysign in 2021 as Director of Data Science, promoted to VP of Operations in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260856,"accession_number":"0001683168-23-007671","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q3 revenue up 17% to $12.4M; net income $1.1M; pharma revenue +142%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenues $12.4M (+17% YoY); net income $1.1M, diluted EPS $0.02.","Adjusted EBITDA $2.3M (+22% YoY); plasma revenue +13%, pharma patient affordability revenue +142%.","Added 19 new plasma centers (462 total); avg revenue per plasma center per month $8,102 (+7.8% YoY).","Exited quarter with $9.9M unrestricted cash, zero debt; repurchased 75k shares for $150k.","FY2023 guidance reaffirmed: revenue $44-46M, Adj. EBITDA $6-7.5M; Q4 growth expected slightly above 17%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":33584666.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278131,"accession_number":"0001683168-23-005405","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q2 revenue up 28% to $11.0M; Adjusted EBITDA $1.1M; guides FY rev $44-46M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.0M, up 28% YoY; net loss $0.1M ($0.00 EPS).","Adjusted EBITDA $1.1M, up 23% YoY; FY 2023 guidance revenue $44-46M, Adj EBITDA $6.0-7.5M.","Added 4 net plasma centers, exit at 443; launched 5 new patient affordability programs, now 31 active.","Pharma patient affordability revenue up 133% to $729K; repurchased 119,558 shares for $312K.","Transitioned 16 mature plasma centers in July, total >460 centers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":21184341.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296233,"accession_number":"0001683168-23-003122","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q1 rev +23% to $10.1M, net loss narrows; Q2 guidance calls for continued growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2023 revenues $10.1M (+23% YoY); net loss $0.2M improved from $0.3M loss a year ago.","Adjusted EBITDA $0.7M (down 22% YoY); guided Q2 rev growth 15-20%, Adj. EBITDA growth 5-10%.","Added 10 plasma centers (total 439); launched 7 pharma copay programs (total 26); gross spend +31%.","Unrestricted cash $6.4M (down $3.3M from Dec 2022) due to AR build, capex, and $0.7M stock buyback.","Gross margin fell to 49.8% from 60.8% on higher third-party costs and mix shift toward lower-margin plasma."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":10143290.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296232,"accession_number":"0001683168-23-003070","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Paysign shareholders approve 2023 Equity Incentive Plan with 5M shares; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2023 Plan approved with ~32.97M for, 0.79M against; replaces 3Pea 2018 plan; 5M shares reserved.","Directors elected: Newcomer, Lanford, Herman, Henry, Mina, Newman, Triplett; all received majority 'for' votes.","Ratification of Moss Adams LLP as auditor for FY2023: ~34.39M for, 9,398 against.","No awards may be made under Prior Plan after effective date; outstanding awards continue under Prior Plan terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316729,"accession_number":"0001683168-23-001818","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Paysign repurchases 200K shares from former director at ~$666K, 90% of VWAP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased 200,000 shares from former director Daniel Spence at 90% of 10-day VWAP; total price $666,018.","Agreement includes a right of first refusal on any future transfers by Spence.","Spence granted irrevocable proxy to CEO, General Counsel, and CFO to vote his remaining shares.","One-year standstill provision prohibits Spence from acquiring additional company shares.","Company paid using available cash; shares retired or held as treasury."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316728,"accession_number":"0001683168-23-001651","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Paysign authorizes $5M stock repurchase program, to run 36 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $5,000,000 of outstanding common stock.","Program starts immediately and is expected to be completed over 36 months.","CEO Mark Newcomer cites confidence in operating results and growth prospects.","Repurchases may be made in open market or private transactions under Rule 10b-18.","Program may be suspended, terminated, or modified at any time at management's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316727,"accession_number":"0001683168-23-001648","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign reports FY2022 revenue $38.0M (+29% YoY), net income $1.0M; guides FY2023 revenue $44-46M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenue $38.0M, up 29% YoY; net income $1.0M ($0.02 diluted EPS) vs net loss of $2.7M in 2021.","Adjusted EBITDA $5.5M, up 175% from $2.0M; Q4 revenue $10.6M, up 21%; Q4 adjusted EBITDA $1.7M, up 38%.","Board authorized $5M share repurchase program; added 78 net plasma centers in 2022, ending with 444.","FY2023 guidance: revenue $44-46M, net income $2.5-3.5M ($0.05-0.06 diluted EPS), adjusted EBITDA $6.0-7.5M.","Pharma copay revenue up 145% to $1.5M; launched 10 new pharma copay programs in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316726,"accession_number":"0001683168-23-001163","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Paysign sets 2023 annual meeting for May 5; proposal deadline March 10","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2023 Annual Meeting scheduled for May 5, 2023; record date March 24, 2023.","Meeting date differs by >30 days from 2022 meeting (Dec 16, 2022), triggering revised deadlines.","Stockholder proposals for proxy inclusion must be received by March 10, 2023.","Proposals and director nominations must be sent to Secretary Robert Strobo at Henderson, NV address.","Company provides notice under Rule 14a-5(f) of the Exchange Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334983,"accession_number":"0001683168-22-008589","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Paysign shareholders elect all seven director nominees and ratify auditor at annual meeting.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Mark R. Newcomer elected with 34,398,763.57 For, 18,677.06 Withheld, 1,834,965 Broker Non-Votes.","Matthew Lanford elected with 34,288,172.57 For, 129,268.06 Withheld, 1,834,965 Broker Non-Votes.","Joan M. Herman elected with 34,150,430.57 For, 267,010.06 Withheld, 1,834,965 Broker Non-Votes.","MOSS ADAMS LLP ratified as auditor with 36,243,523.57 For, 4,787.06 Against, 4,095.00 Abstain, 0 Broker Non-Votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334982,"accession_number":"0001683168-22-007393","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q3 2022 revenue $10.6M (+36% YoY); net income $0.85M; guides FY2022 rev $38.15-38.35M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.6M (+36% YoY); net income $0.85M vs loss of $0.27M in Q3 2021; diluted EPS $0.02.","Adjusted EBITDA $1.9M ($0.04 per diluted share); gross margin improved to 54%.","FY2022 revenue guidance $38.15M-$38.35M (29-30% growth); adjusted EBITDA expected $5.50-$5.60M.","Added 13 plasma donation centers in Q3, ending with 450 centers; plasma revenue up 40% YoY.","Unrestricted cash $8.0M; federal injunction allows Mexican nationals to donate plasma again."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":27415843.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334981,"accession_number":"0001683168-22-006942","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-10-18T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Paysign reschedules 2022 Annual Meeting to Dec 16, updates proposal deadlines","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting moved from Oct 28 to Dec 16, 2022; record date set as Oct 21, 2022.","Deadline for stockholder proposals (including director nominations) is Oct 28, 2021 per filing.","Prior 2021 proxy-statement deadlines no longer apply due to more-than-30-day date change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352443,"accession_number":"0001683168-22-006183","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-09-02T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Paysign sets 2022 annual meeting for Oct 28, 2022; stockholder proposal deadline Sept 12, 2021 per filing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting will be held on October 28, 2022; record date is August 31, 2022.","Deadline for Rule 14a-8 stockholder proposals is September 12, 2021 (date as stated in filing).","Proposals must be submitted in writing to Secretary Robert Strobo at Paysign's Henderson, NV address.","Meeting date differs by over 30 days from 2021 meeting (Aug 5, 2021), triggering new deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352442,"accession_number":"0001683168-22-005471","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q2 revenue $8.6M (+29% YoY); net loss narrows to $0.2M; adds 62 plasma centers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.6M, up 29% YoY; net loss $0.2M vs $0.7M loss last year; adjusted EBITDA $0.9M.","Added 62 plasma centers in Q2, exiting with 437 centers; gross dollar load up 40.5% YoY.","FY2022 revenue guidance raised to high end of $35.25M-$38.35M (27.5% growth); Q3 rev ~$10.2M, Q4 ~$10.5M.","Gross margin improved to 55%; engaged Moss Adams LLP as new auditor; unrestricted cash $6.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":16819415.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352441,"accession_number":"0001683168-22-005468","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Paysign board member Daniel Spence resigns; President Matt Lanford appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel H. Spence, co-founder, resigned from board effective Aug 8, 2022; no disagreement with company.","Matt Lanford, President and COO since Feb 2021, appointed to board same day, replacing Spence.","Lanford will be a non-independent director and will not serve on any board committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352440,"accession_number":"0001683168-22-005283","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Paysign appoints Moss Adams LLP as independent auditor for FY2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee selected Moss Adams LLP after competitive process; effective June 11, 2022.","No prior consultation with Moss Adams on accounting principles or disagreements in past two years.","No reportable events within Item 304(a)(1)(v) during prior fiscal years or interim period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369966,"accession_number":"0001683168-22-003450","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q1 revenue $8.2M (+31% YoY), net loss $0.3M; reaffirms FY2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.2M vs $6.3M in Q1 2021; net loss $0.3M (($0.01) per share).","Plasma revenue up 37% to $7.4M; added 9 new centers, exiting with 375 total.","Pharma revenue down 9% to $0.8M; launched 4 new copay programs during quarter.","Adjusted EBITDA positive at $0.9M ($0.02/share) vs negative in Q1 2021.","FY2022 outlook unchanged: revenue $35.25M-$38.35M, adj. EBITDA at least $4.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":8220639.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369965,"accession_number":"0001683168-22-002478","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Paysign's auditor BDO USA resigns; no disagreements reported","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Auditor BDO USA, LLP resigned effective upon filing of Q1 2022 Form 10-Q.","No disagreements or reportable events during 2020-2021 and interim period through April 6, 2022.","Audit reports for 2020 and 2021 were unqualified with no adverse opinions.","BDO's letter to SEC filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389087,"accession_number":"0001683168-22-001836","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q4 2021 rev $8.8M, net income $0.1M; FY22 guidance rev $35.3-38.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total rev $8.8M (+21% YoY); net income $0.1M vs loss; adj EBITDA $1.3M.","FY 2021 rev $29.5M (+22% YoY); net loss $2.7M (improvement $6.4M); adj EBITDA $2.0M.","Exit 2021 with 366 plasma centers, +26 from 2020; 4.3M cardholders.","FY22 guidance: rev $35.25-38.35M (20-30% growth); adj EBITDA ≥$4.0M; gross margin 50-52.5%.","Unrestricted cash $7.4M at 12/31/21; mgmt expects sufficient liquidity for next 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407018,"accession_number":"0001683168-21-005354","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q3 revenue $7.8M; plasma $7.0M (+35.6% YoY); net loss $0.3M; raises adj. EBITDA guidance to $1.3-1.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $7.8M for Q3 2021, up $1.1M (16.8%) from Q2 2021 and $7.9M from year-ago.","Plasma revenue $7.0M (+35.6% YoY); added 3 plasma centers for a total of 359.","Net loss of $0.3M ($0.01 per diluted share) compared to net loss of $6.2M in Q3 2020.","Adjusted EBITDA $1.0M ($0.02 per share) vs. $0.3M loss a year ago; FY forecast raised to $1.3-1.9M.","Gross profit margin guidance raised 250 bps to 49.0% for full year 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":20697907.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407017,"accession_number":"0001683168-21-004727","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2021-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Paysign EVP Daniel H. Spence departs effective Sept 30; remains advisor and board member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment of EVP Daniel H. Spence ended September 30, 2021.","Spence will continue as advisor and remain on board until next annual meeting or earlier resignation/removal.","No replacement for the EVP role has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426023,"accession_number":"0001683168-21-003392","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Paysign Q2 2021 revenue $6.7M (+3.2% YoY); net loss $0.9M; raises adjusted EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $6.7M (+3.2% YoY); net loss $0.9M (($0.02) diluted EPS).","Plasma revenue $5.9M (+30.1% YoY); added 13 centers, ending with 356 vs 290 a year ago.","FY2021 revenue outlook maintained at $29M-$32M; adjusted EBITDA guidance raised to $0.75M-$1.90M.","Gross profit margin forecast raised 150bps to 46.5%; operating expenses expected $18.0M-$18.5M.","Total gross dollar load volume +34.7%; purchase transactions +19.1% versus prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":12930718.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426022,"accession_number":"0001683168-21-003356","cik":1496443,"company_name":"Paysign, Inc.","ticker":"PAYS","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PaySign stockholders elect all seven director nominees; BDO USA ratified as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with substantial votes; highest total 33.8M for Bruce Mina and Dennis Triplett.","BDO USA, LLP ratified as independent auditor for FY2021 with 34.6M for, 26.8K against, 7.7K abstentions.","Annual meeting held August 5, 2021; broker non-votes 751,558 for each director proposal.","Proposals covered director elections and auditor ratification; no other matters submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":403723548.8301687,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}